lactic acid has been researched along with everolimus in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (47.37) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, C; Fitzgerald, PJ; Gerckens, U; Grube, E; Honda, Y; Ikeno, F; Kar, S; Lansky, AJ; Sonoda, S | 1 |
| Armstrong, G; Ormiston, JA; Webster, MW | 1 |
| Hossainy, S; Prabhu, S | 1 |
| Chevalier, B; de Bruyne, B; Dudek, D; Ormiston, JA; Serruys, PW; Tanimoto, S; Thuesen, L | 1 |
| Lemos, PA | 1 |
| Bruining, N; Ligthart, JM; Radeva, P; Rotger, D; Serruys, PW; Tanimoto, S; van Domburg, RT | 1 |
| Davies, MC; Hossainy, S; Kleiner, L; Roberts, CJ; Tang, FW; Wu, M | 2 |
| Carter, TP; Feder, D; Hancock, L; Kamberi, M; Myo-Min, K; Nayak, S | 1 |
| Ormiston, JA; Serruys, PW | 1 |
| Brandes, AH; Chaumeil, MM; Dafni, H; Haas-Kogan, DA; James, CD; Kurhanewicz, J; Nelson, SJ; Ronen, SM; Sukumar, S; Vancriekinge, M; Venkatesh, HS; Vigneron, DB; Ward, CS | 1 |
| Bruining, N; Cheong, WF; de Winter, S; Dudek, D; Hamers, R; Heller, I; Miquel-Hebert, K; Onuma, Y; Ormiston, JA; Regar, E; Roelandt, JR; Serruys, PW; Thuesen, L; van Domburg, RT; Veldhof, S; Webster, MW | 1 |
| Chaumeil, MM; Haas-Kogan, DA; James, CD; Ronen, SM; Venkatesh, HS; Ward, CS | 1 |
| Brugaletta, S; Chevalier, B; de Bruyne, B; Dudek, D; Gijsen, F; Gutiérrez-Chico, JL; McClean, DR; Onuma, Y; Ormiston, J; Regar, E; Serruys, PW; Thuesen, L; Wentzel, J; Whitbourn, R; Windecker, S | 1 |
| Campos, CM; Cho, YK; Dijkstra, J; Eggermont, J; Garcia-Garcia, HM; Ishibashi, Y; Kamberi, M; Lane, J; Nakatani, S; Onuma, Y; Perkins, L; Rapoza, R; Reiber, JH; Serruys, PW; Sheehy, A | 1 |
| Arana, C; Dager, A; Delgado, JA; Gasior, P; Généreux, P; Granada, JF; Hernandez, H; Higuera, S; Maehara, A; Moncada, M; Vesga, B | 1 |
| Guthy, D; Laborde, L; McSheehy, P; Oz, F; Ristov, M; Sterker, D | 1 |
| Mukete, BN; van der Heijden, LC; von Birgelen, C | 1 |
| Cui, J; Guo, Y; Peng, T; Wu, H; Xiong, J | 1 |
1 review(s) available for lactic acid and everolimus
| Article | Year |
|---|---|
Bioabsorbable coronary stents.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Drug-Eluting Stents; Everolimus; Humans; Lactic Acid; Magnesium; Polycarboxylate Cement; Polyesters; Polymers; Prosthesis Design; Sirolimus; Stents; Thrombosis; Time Factors; Treatment Outcome | 2009 |
2 trial(s) available for lactic acid and everolimus
| Article | Year |
|---|---|
Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer.
Topics: Aged; Anticoagulants; Catheterization; Cineangiography; Coated Materials, Biocompatible; Comorbidity; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Drug Implants; Everolimus; Female; Follow-Up Studies; Growth Inhibitors; Humans; Hyperplasia; Immunosuppressive Agents; Lactic Acid; Male; Middle Aged; Myocardial Infarction; Polyesters; Polymers; Prospective Studies; Single-Blind Method; Sirolimus; Stainless Steel; Stents; Treatment Outcome; Tunica Intima; Ultrasonography, Interventional | 2004 |
Monitoring in vivo absorption of a drug-eluting bioabsorbable stent with intravascular ultrasound-derived parameters a feasibility study.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Europe; Everolimus; Feasibility Studies; Humans; Image Interpretation, Computer-Assisted; Lactic Acid; New Zealand; Polyesters; Polymers; Predictive Value of Tests; Prosthesis Design; Sirolimus; Solubility; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2010 |
16 other study(ies) available for lactic acid and everolimus
| Article | Year |
|---|---|
First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent.
Topics: Absorbable Implants; Angina Pectoris; Coronary Angiography; Drug Delivery Systems; Everolimus; Humans; Immunosuppressive Agents; Lactic Acid; Male; Middle Aged; Polyesters; Polymers; Sirolimus; Stents; Ultrasonography, Interventional | 2007 |
Modeling of degradation and drug release from a biodegradable stent coating.
Topics: Coated Materials, Biocompatible; Drug Delivery Systems; Everolimus; Humans; Immunosuppressive Agents; Lactic Acid; Models, Theoretical; Polyesters; Polymers; Sirolimus; Stents | 2007 |
Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials.
Topics: Aged; Angioplasty, Balloon, Coronary; Biocompatible Materials; Biomechanical Phenomena; Cardiovascular Agents; Chromium Alloys; Clinical Trials as Topic; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Female; Humans; Lactic Acid; Male; Middle Aged; Polyesters; Polymers; Prosthesis Design; Research Design; Sirolimus; Tomography, Optical Coherence | 2007 |
Polymeric stents: degradable but strong.
Topics: Angioplasty, Balloon, Coronary; Biocompatible Materials; Biomechanical Phenomena; Cardiovascular Agents; Chromium Alloys; Coronary Angiography; Coronary Artery Disease; Drug-Eluting Stents; Everolimus; Humans; Lactic Acid; Polyesters; Polymers; Prosthesis Design; Sirolimus | 2007 |
Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology.
Topics: Aged; Biocompatible Materials; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Everolimus; Female; Humans; Immunosuppressive Agents; Lactic Acid; Male; Middle Aged; Polyesters; Polymers; Sirolimus; Time Factors | 2008 |
Nanoscale mechanical measurement determination of the glass transition temperature of poly(lactic acid)/everolimus coated stents in air and dissolution media.
Topics: Everolimus; Glass; Hot Temperature; Lactic Acid; Microscopy, Atomic Force; Nanotechnology; Polyesters; Polymers; Sirolimus; Solubility; Stents | 2009 |
A novel accelerated in vitro release method for biodegradable coating of drug eluting stents: Insight to the drug release mechanisms.
Topics: Absorbable Implants; Chromatography, Gel; Drug-Eluting Stents; Electrons; Everolimus; Excipients; Immunosuppressive Agents; Lactic Acid; Microscopy, Electron, Scanning; Molecular Weight; Pharmaceutical Preparations; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sirolimus; Solubility; Solvents | 2009 |
Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy.
Topics: Animals; Carbon Isotopes; Chromones; Drug Delivery Systems; Enzyme Inhibitors; Everolimus; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Monitoring, Physiologic; Morpholines; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Sirolimus; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Surface characterization of poly(lactic acid)/everolimus and poly(ethylene vinyl alcohol)/everolimus stents.
Topics: Biocompatible Materials; Cytostatic Agents; Diffusion; Drug Delivery Systems; Drug-Eluting Stents; Everolimus; Hydrophobic and Hydrophilic Interactions; Kinetics; Lactic Acid; Microscopy, Atomic Force; Photoelectron Spectroscopy; Polyesters; Polymers; Polyvinyls; Sirolimus; Spectrophotometry, Infrared; Surface Properties | 2010 |
Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Chromones; Enzyme Inhibitors; Everolimus; Glioblastoma; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Differences in neointimal thickness between the adluminal and the abluminal sides of malapposed and side-branch struts in a polylactide bioresorbable scaffold: evidence in vivo about the abluminal healing process.
Topics: Absorbable Implants; Aged; Angioplasty, Balloon, Coronary; Australia; Cardiovascular Agents; Cell Proliferation; Coated Materials, Biocompatible; Coronary Artery Disease; Coronary Vessels; Europe; Everolimus; Female; Humans; Lactic Acid; Male; Middle Aged; Neointima; New Zealand; Polyesters; Polymers; Predictive Value of Tests; Prosthesis Design; Registries; Sirolimus; Time Factors; Tissue Scaffolds; Tomography, Optical Coherence; Treatment Outcome | 2012 |
Echogenicity as a surrogate for bioresorbable everolimus-eluting scaffold degradation: analysis at 1-, 3-, 6-, 12- 18, 24-, 30-, 36- and 42-month follow-up in a porcine model.
Topics: Absorbable Implants; Angioplasty, Balloon, Coronary; Animals; Cardiovascular Agents; Coronary Vessels; Crystallization; Drug-Eluting Stents; Everolimus; Lactic Acid; Linear Models; Models, Animal; Observer Variation; Polyesters; Polymers; Predictive Value of Tests; Prosthesis Design; Reproducibility of Results; Swine; Time Factors; Ultrasonography, Interventional | 2015 |
Three-month evaluation of strut healing using a novel optical coherence tomography analytical method following bioresorbable polymer everolimus-eluting stent implantation in humans: the TIMELESS study.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Cardiovascular Agents; Chromium; Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Drug Therapy, Combination; Drug-Eluting Stents; Everolimus; Female; Humans; Lactic Acid; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platinum; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Predictive Value of Tests; Prosthesis Design; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Wound Healing | 2017 |
Continuous low plasma concentrations of everolimus provides equivalent efficacy to oral daily dosing in mouse xenograft models of human cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Chromatography, Liquid; Drug Administration Schedule; Everolimus; Female; Humans; Inhibitory Concentration 50; Kidney Neoplasms; Lactic Acid; Mice; Mice, Nude; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2017 |
Reply to Letter to the Editor entitled: "Bioresorbable stent thrombosis, lactic acid release and Kounis syndrome".
Topics: Absorbable Implants; Drug-Eluting Stents; Everolimus; Humans; Lactic Acid; Thrombosis; Treatment Outcome | 2017 |
Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Glucose; Humans; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |